Sigma-Aldrich Introduces the MyriaScreen Diversity Collection for Drug Discovery
Natick, MA – Sigma-Aldrich (NASDAQ:SIAL) is pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds. The collection, produced in collaboration with TimTec Inc. (http://www.timtec.net), is the result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections. The MyriaScreen Diversity Collection is comprised of 10,000 high-purity screening compounds handpicked to maximize chemical diversity while maintaining drug-likeness.
The MyriaScreen Diversity Collection was assembled from a pool of over 300,000 screening compounds using a combination of filters, diversity predictors, and manual selection. The resulting 10,000 compounds are drug-like, chemically diverse, and amenable to follow-up chemistry and optimization. The collection is well suited for researchers that are looking for a small, cost-effective, ready-to-screen set of high-quality screening compounds.
“MyriaScreen will complement our customers’ existing screening collections and jump-start new collections by quickly adding interesting chemotypes,” said Michael Earley, Product Manager, Drug Discovery, Sigma-Aldrich. “Our collaboration with TimTec, Inc. resulted in a high-quality library that our customers will find useful.”
About Sigma-Aldrich
Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and chemical manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 34 countries and has 6,000 employees providing excellent service worldwide. We are committed to the success of our Customers, Employees and Shareholders through leadership in Life Science, High Technology and Service.
Sigma-Aldrich Press Release
This release contains forward-looking statements relating to future performance, goals, strategic actions
and initiatives and similar intentions and beliefs and other statements regarding the Company’s expectations, goals, beliefs, intentions and the like, which involve assumptions regarding Company operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
To request information about MyriaScreen, please visit http://www.sigmaaldrich.com/Area_of_Interest/Chemistry/Drug_Discovery.html
Forward Inquiries to:
Mrs. Kelley Euchner, 800-521-8956
Mr. Timothy Sommer, 314-286-7768
About TimTec
TimTec Corporation is a privately held company located in Newark Delaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. The company has developed strong in-house expertise assembling general and targeted library collections for variety of research purposes. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.
For further information please contact:
TimTec Inc
301 A Ruthar Drive
Newark DE 19711
Tel 302 292 8500
Fax 302 292 8520
info@timtec.net
http://www.timtec.net
